Anti-obesity agents
    12.
    发明授权
    Anti-obesity agents 失效
    抗肥胖剂

    公开(公告)号:US07906482B2

    公开(公告)日:2011-03-15

    申请号:US11923222

    申请日:2007-10-24

    IPC分类号: C07K14/00 A61K38/00

    摘要: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.

    摘要翻译: 本发明涉及包含与反应性基团偶联的PYY肽或其功能性衍生物的化合物。 这样的反应性基团能够对血液成分进行反应,与其形成稳定的共价键。 本发明还涉及包含共价键合到血液成分上的化合物的缀合物。 此外,本发明还涉及在患者中增强PYY肽或其功能性衍生物的抗肥胖活性的方法。

    Anti-obesity agents
    13.
    发明授权
    Anti-obesity agents 失效
    抗肥胖剂

    公开(公告)号:US07601691B2

    公开(公告)日:2009-10-13

    申请号:US11067556

    申请日:2005-02-25

    IPC分类号: C07K14/00 A61K38/00

    摘要: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.

    摘要翻译: 本发明涉及包含与反应性基团偶联的PYY肽或其功能性衍生物的化合物。 这样的反应性基团能够对血液成分进行反应,与其形成稳定的共价键。 本发明还涉及包含共价键合到血液成分上的化合物的缀合物。 此外,本发明还涉及在患者中增强PYY肽或其功能性衍生物的抗肥胖活性的方法。

    THOMBOPOIETIN PEPTIDE CONJUGATES
    17.
    发明申请
    THOMBOPOIETIN PEPTIDE CONJUGATES 审中-公开
    THOMBOPOIETIN胶原蛋白

    公开(公告)号:US20090054332A1

    公开(公告)日:2009-02-26

    申请号:US12143780

    申请日:2008-06-21

    摘要: The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention typically exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and typically exhibit increased biological activity compared to the unconjugated peptides. The present invention also provides methods for the treatment and prevention of a disease or disorder comprising the administration of one or more of the compounds or conjugates of the invention to a subject in need of such treatment or prevention.

    摘要翻译: 本发明涉及包含修饰的血小板生成素肽和这种修饰肽与血清成分(通常为血清蛋白或肽)的缀合物的化合物。 本发明的化合物和缀合物包含反应性基团或反应性基团的残基,其可任选地通过连接基团与修饰的肽共价连接。 本发明还提供了将修饰的肽共价连接到血清蛋白或肽以形成本发明的缀合物的方法。 与相应的未结合的肽相比,本发明的缀合物通常表现出较长的体内循环半衰期。 本发明的缀合物还保留非共轭肽的至少一些生物活性,并且与非共轭多肽相比通常表现出增加的生物学活性。 本发明还提供了治疗和预防疾病或病症的方法,包括将本发明的一种或多种化合物或缀合物施用于需要这种治疗或预​​防的受试者。